Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.
children
high-risk medulloblastoma
phase II trial
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
31
12
2020
medline:
5
8
2021
entrez:
30
12
2020
Statut:
ppublish
Résumé
High-risk medulloblastoma is defined by the presence of metastatic disease and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC amplification. We aimed to assess the 3-year progression-free survival (PFS) and define the molecular characteristics associated with PFS in patients aged 5-19 years with newly diagnosed high-risk medulloblastoma treated according to the phase II trial PNET HR+5. All children received postoperative induction chemotherapy (etoposide and carboplatin), followed by 2 high-dose thiotepa courses (600 mg/m2) with hematological stem cell support. At the latest 45 days after the last stem cell rescue, patients received risk-adapted craniospinal radiation therapy. Maintenance treatment with temozolomide was planned to start between 1-3 months after the end of radiotherapy. The primary endpoint was PFS. Outcome and safety analyses were per protocol (all patients who received at least one dose of induction chemotherapy). Fifty-one patients (median age, 8 y; range, 5-19) were enrolled. The median follow-up was 7.1 years (range: 3.4-9.0). The 3 and 5-year PFS with their 95% confidence intervals (95% CI) were 78% (65-88) and 76% (63-86), and the 3 and 5-year OS were 84% (72-92) and 76% (63-86), respectively. Medulloblastoma subtype was a statistically significant prognostic factor (P-value = 0.039) with large-cell/anaplastic being of worse prognosis, as well as a molecular subgroup (P-value = 0.012) with sonic hedgehog (SHH) and group 3 being of worse prognosis than wingless (WNT) and group 4. Therapy was well tolerated. This treatment based on high-dose chemotherapy and conventional radiotherapy resulted in a high survival rate in children with newly diagnosed high-risk medulloblastoma.
Sections du résumé
BACKGROUND
High-risk medulloblastoma is defined by the presence of metastatic disease and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC amplification. We aimed to assess the 3-year progression-free survival (PFS) and define the molecular characteristics associated with PFS in patients aged 5-19 years with newly diagnosed high-risk medulloblastoma treated according to the phase II trial PNET HR+5.
METHODS
All children received postoperative induction chemotherapy (etoposide and carboplatin), followed by 2 high-dose thiotepa courses (600 mg/m2) with hematological stem cell support. At the latest 45 days after the last stem cell rescue, patients received risk-adapted craniospinal radiation therapy. Maintenance treatment with temozolomide was planned to start between 1-3 months after the end of radiotherapy. The primary endpoint was PFS. Outcome and safety analyses were per protocol (all patients who received at least one dose of induction chemotherapy).
RESULTS
Fifty-one patients (median age, 8 y; range, 5-19) were enrolled. The median follow-up was 7.1 years (range: 3.4-9.0). The 3 and 5-year PFS with their 95% confidence intervals (95% CI) were 78% (65-88) and 76% (63-86), and the 3 and 5-year OS were 84% (72-92) and 76% (63-86), respectively. Medulloblastoma subtype was a statistically significant prognostic factor (P-value = 0.039) with large-cell/anaplastic being of worse prognosis, as well as a molecular subgroup (P-value = 0.012) with sonic hedgehog (SHH) and group 3 being of worse prognosis than wingless (WNT) and group 4. Therapy was well tolerated.
CONCLUSIONS
This treatment based on high-dose chemotherapy and conventional radiotherapy resulted in a high survival rate in children with newly diagnosed high-risk medulloblastoma.
Identifiants
pubmed: 33377141
pii: 6055191
doi: 10.1093/neuonc/noaa301
pmc: PMC8248855
doi:
Substances chimiques
Hedgehog Proteins
0
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1163-1172Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Acta Neuropathol. 2012 Apr;123(4):615-26
pubmed: 22057785
J Clin Oncol. 2016 Dec;34(34):4151-4160
pubmed: 27863192
J Clin Oncol. 2009 Apr 10;27(11):1879-83
pubmed: 19273707
Lancet Oncol. 2017 Jul;18(7):958-971
pubmed: 28545823
Neuro Oncol. 2015 Mar;17(3):448-56
pubmed: 25395462
Radiology. 1969 Dec;93(6):1351-9
pubmed: 4983156
J Clin Oncol. 2009 Feb 1;27(4):566-71
pubmed: 19075266
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
Int J Surg Oncol. 2012;2012:245385
pubmed: 22312539
J Clin Oncol. 2019 Mar 20;37(9):731-740
pubmed: 30730781
J Med Imaging Radiat Oncol. 2014 Dec;58(6):683-90
pubmed: 25224299
Endocr Relat Cancer. 2004 Dec;11(4):589-602
pubmed: 15613441
Med Pediatr Oncol. 1995 Feb;24(2):104-8
pubmed: 7990757
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):499-508
pubmed: 16517093
Pediatr Blood Cancer. 2015 Feb;62(2):329-334
pubmed: 25327609
Eur J Cancer. 2009 May;45(7):1209-1217
pubmed: 19250820
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Lancet Oncol. 2006 Oct;7(10):813-20
pubmed: 17012043
J Pediatr. 1983 Oct;103(4):562-5
pubmed: 6620016
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Oncotarget. 2015 Nov 17;6(36):38827-39
pubmed: 26420814
Pediatr Blood Cancer. 2014 Aug;61(8):1398-402
pubmed: 24664937
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
BMC Cancer. 2018 Feb 13;18(1):177
pubmed: 29433564
J Clin Oncol. 2012 Jul 20;30(21):2648-53
pubmed: 22665539
Med Pediatr Oncol. 1989;17(2):92-6
pubmed: 2704342
Neuro Oncol. 2013 Jan;15(1):97-103
pubmed: 23099653
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931